Brain-heart axis in adults with type 2 diabetes
Official title: Effects of Metabolic Dysfunction on Functional Capacity and Mental Health Through the Brain-Heart Axis in Type 2 Diabetes Mellitus: A Cross-Sectional Study Based on Electroencephalography and Heart Rate Variability
Run by Hacettepe University · NCT07757308 · Data updated 2026-11-12
This study tests how brain activity and heart regulation relate to metabolic status in adults with type 2 diabetes to understand cognitive and functional health.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 75 Years |
| Sex | All |
| Enrollment | 46 (estimated) |
| Sponsor | Hacettepe University Academic / other |
| Locations | 1 site (Tunceli) |
| Status | Recruiting |
| Started | June 25, 2026 |
| Main results expected | September 15, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT07757308 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40-75 with a confirmed diagnosis of type 2 diabetes who can complete the assessments and provide informed consent.
✕Probably not a fit
Individuals unable to complete the assessment protocol or with neurological, psychiatric, or other conditions that influence the outcomes may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cross-sectional study will assess how metabolic abnormalities in adults with type 2 diabetes relate to brain activity and autonomic cardiovascular regulation. Participants will undergo resting EEG, heart rate variability measurements, and functional capacity tests to explore connections between metabolic status, brain-heart interactions, cognitive performance, and mental well-being. The goal is to identify biomarkers and patterns that link metabolic control with neural and autonomic function, potentially informing future interventions. No intervention is applied; the study describes associations at a single time point.
Why it matters
Potential benefit: If successful, findings could help identify brain-heart biomarkers associated with metabolic health in type 2 diabetes and guide future prevention or management strategies.
How similar studies have gone: Prior research has explored EEG and heart rate variability separately in diabetes, but few have integrated these measures to study brain-heart axis relationships in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 40 to 75 years. * Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM). * Able to understand the study procedures and provide written informed consent. * Able to complete all planned clinical, neurophysiological, cognitive, and functional assessments. Exclusion Criteria: * Diagnosis of neurological, psychiatric, orthopedic, or other systemic diseases that may influence study outcomes. * Cognitive or psychological impairment preventing completion of study assessments. * History of recent surgery or acute medical condition affecting participation. * Inability or unwillingness to provide written informed consent. * Inability to complete the assessment protocol.
Where it's running
-
Munzur University Faculty of Health Sciences
Tunceli, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Ceyhun TOPCUOGLU, Dr.
- Email: ceyhuntopcuoglu1@gmail.com
- Phone: +90 535 653 51 37
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lifestyle change program to help type 2 diabetes go into remission in Pakistan
This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
MWN105 injection in overweight or obese adults you may join
This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.
-
MWN109 tablets in adults with type 2 diabetes mellitus
A phase 2 trial tests MWN109 tablets versus placebo (and against active control semaglutide) to see if the medicine helps adults with type 2 diabetes lower their blood sugar.
-
Digital dietary help for people on GLP-1 therapy to reach better blood sugar and weight
This trial tests whether adding a digital dietary program (NutriSteppe) to usual care helps adults on GLP-1 medications see better blood sugar control and weight results.
-
Cilostazol and Aspirin to Prevent Heart and Brain Events in Type 2 Diabetes
In people with type 2 diabetes and higher cardiovascular risk, researchers are testing whether taking cilostazol plus aspirin can help reduce major heart and brain events.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.